CoChat

Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis

Ding, Donglin, Blee, Alexandra M., Zhang, Jianong, Pan, Yunqian, Becker, Nicole A., Maher, L. James, Jimenez, Rafael, Wang, Liguo, Huang, Haojie · 2023 · Nature Communications
Cited by 27

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Whether TMPRSS2-ERG fusion and TP53 gene alteration coordinately promote prostate cancer (PCa) remains unclear. Here we demonstrate that TMPRSS2-ERG fusion and TP53 mutation / deletion co-occur in PCa patient specimens and this co-occurrence accelerates prostatic oncogenesis. p53 gain-of-function (GOF) mutants are now shown to bind to a unique DNA sequence in the CTNNB1 gene promoter and transactivate its expression. ERG and β-Catenin co-occupy sites at pyrimidine synthesis gene (PSG) loci and promote PSG expression, pyrimidine synthesis and PCa growth. β-Catenin inhibition by small molecule inhibitors or oligonucleotide-based PROTAC suppresses TMPRSS2-ERG- and p53 mutant-positive PCa cell growth in vitro and in mice. Our study identifies a gene transactivation function of GOF mutant p53 and reveals β-Catenin as a transcriptional target gene of p53 GOF mutants and a driver and therapeutic target of TMPRSS2-ERG- and p53 GOF mutant-positive PCa.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-40352-4

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 57

  1. Lane, D. P. How to lose tumor suppression. Science 365, 539–540 (2019). · DOI
  2. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014). · DOI · Paper page
  3. Sigal, A. & Rotter, V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60, 6788–6793 (2000).
  4. el-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817–825 (1993). · DOI · Paper page
  5. Nakano, K. & Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7, 683–694 (2001). · DOI · Paper page
  6. Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W. & Vogelstein, B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7, 673–682 (2001). · DOI · Paper page
  7. Dittmer, D. et al. Gain of function mutations in p53. Nat. Genet 4, 42–46 (1993). · DOI · Paper page
  8. Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev. 26, 1268–1286 (2012). · DOI · Paper page
  9. Do, P. M. et al. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev. 26, 830–845 (2012). · DOI · Paper page
  10. Kim, M. P. et al. Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discov. 11, 2094–2111 (2021). · DOI · Paper page
  11. Zhu, J. et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525, 206–211 (2015). · DOI · Paper page
  12. Porubiakova, O. et al. The influence of quadruplex structure in proximity to P53 target sequences on the transactivation potential of P53 alpha isoforms. Int. J. Mol. Sci. 21, 127 (2019). · DOI
  13. Quante, T. et al. Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity. Cell Cycle 11, 3290–3303 (2012). · DOI · Paper page
  14. Loughran, S. J. et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat. Immunol. 9, 810–819 (2008). · DOI · Paper page
  15. Yang, H. et al. ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas. Elife 4, e10870 (2015). · DOI · Paper page
  16. Cancer Genome Atlas Research, N. The molecular taxonomy of primary prostate cancer. Cell 163, 1011–1025 (2015). · DOI · Paper page
  17. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005). · DOI · Paper page
  18. Chen, Y. et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat. Med. 19, 1023–1029 (2013). · DOI · Paper page
  19. Kron, K. J. et al. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nat. Genet. 49, 1336–1345 (2017). · DOI · Paper page
  20. Carver, B. S. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619–624 (2009). · DOI · Paper page
  21. King, J. C. et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 41, 524–526 (2009). · DOI · Paper page
  22. Nguyen, L. T. et al. ERG activates the YAP1 Transcriptional program and induces the development of age-related prostate tumors. Cancer Cell 27, 797–808 (2015). · DOI · Paper page
  23. Yang, Y. et al. Loss of FOXO1 cooperates with TMPRSS2-ERG overexpression to promote prostate tumorigenesis and cell invasion. Cancer Res. 77, 6524–6537 (2017). · DOI
  24. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020). · DOI · Paper page
  25. Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015). · DOI · Paper page
  26. Meyers, F. J. et al. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 83, 2534–2539 (1998). · doi:10.1002/(sici)1097-0142(19981215)83:12<2534::aid-cncr19>3.0.co;2-v
  27. Wu, X. et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101, 61–69 (2001). · DOI · Paper page
  28. Klezovitch, O. et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl. Acad. Sci. USA 105, 2105–2110 (2008). · DOI · Paper page
  29. Garavito, M. F., Narvaez-Ortiz, H. Y. & Zimmermann, B. H. Pyrimidine metabolism: dynamic and versatile pathways in pathogens and cellular development. J. Genet Genom. 42, 195–205 (2015). · DOI · Paper page
  30. Blee, A. M. et al. TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer. Clin. Cancer Res. 24, 4551–4565 (2018). · DOI
  31. Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell 127, 469–480 (2006). · DOI · Paper page
  32. Plotnik, J. P., Budka, J. A., Ferris, M. W. & Hollenhorst, P. C. ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells. Nucleic Acids Res. 42, 11928–11940 (2014). · DOI
  33. Watanabe, K. et al. Integrative ChIP-seq/microarray analysis identifies a CTNNB1 target signature enriched in intestinal stem cells and colon cancer. PLoS One 9, e92317 (2014). · DOI · Paper page
  34. Arima, T., Akiyoshi, H. & Fujii, S. Characterization of pyrimidine nucleoside monophosphokinase in normal and malignant tissues. Cancer Res. 37, 1593–1597 (1977).
  35. Fan, P. et al. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. Cancer Lett. 373, 130–137 (2016). · DOI
  36. Wonganan, P. et al. Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells. Cancer Biol. Ther. 13, 908–914 (2012). · doi:10.4161/cbt.20843
  37. Bepler, G. et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 24, 4731–4737 (2006). · DOI · Paper page
  38. Emami, K. H. et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc. Natl. Acad. Sci. USA 101, 12682–12687 (2004). · DOI · Paper page
  39. Osawa, Y. et al. Inhibition of Cyclic Adenosine Monophosphate (cAMP)-response Element-binding Protein (CREB)-binding Protein (CBP)/beta-Catenin reduces liver fibrosis in mice. EBioMedicine 2, 1751–1758 (2015). · DOI · Paper page
  40. Hrckulak, D., Kolar, M., Strnad, H. & Korinek, V. TCF/LEF transcription factors: an update from the internet resources. Cancers 8, 70 (2016). · DOI · Paper page
  41. Kumar, A. et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl. Acad. Sci. USA 108, 17087–17092 (2011). · DOI · Paper page
  42. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011). · DOI · Paper page
  43. Robitaille, A. M. et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320–1323 (2013). · DOI · Paper page
  44. Gu, X. et al. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia 35, 1023–1036 (2021). · DOI
  45. Valvezan, A. J. et al. mTORC1 couples nucleotide synthesis to nucleotide demand resulting in a targetable metabolic vulnerability. Cancer Cell 32, 624–638.e625 (2017). · DOI · Paper page
  46. Wang, X. et al. Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. Sci. Transl. Med. 11, eaau4972 (2019). · DOI · Paper page
  47. Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H. J. & Ladner, R. D. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat. Rev. Clin. Oncol. 11, 282–298 (2014). · DOI · Paper page
  48. Adorno, M. et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137, 87–98 (2009). · DOI · Paper page
  49. Liu, K., Ling, S. & Lin, W. C. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol. Cell Biol. 31, 4464–4481 (2011). · DOI · Paper page
  50. Wu, L. et al. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Res. 73, 6068–6079 (2013). · DOI
  51. Meerbrey, K. L. et al. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc. Natl. Acad. Sci. USA 108, 3665–3670 (2011). · DOI · Paper page
  52. Drost, J. et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc. 11, 347–358 (2016). · DOI · Paper page
  53. Ding, D. et al. Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer. Nat. Commun. 13, 6311 (2022).
  54. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013). · DOI · Paper page
  55. Wang, L., Wang, S. & Li, W. RSeQC: quality control of RNA-seq experiments. Bioinformatics 28, 2184–2185 (2012). · DOI · Paper page
  56. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
  57. McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495–501 (2010). · DOI · Paper page

Cited by

See all 27

Metadata

Authors
Ding, D., Blee, A. M., Zhang, J., Pan, Y., Becker, N. A., Maher, L. J., Jimenez, R., Wang, L., & Huang, H.
Venue
Nature Communications
Published
2023-08-03
Volume
14
Issue
1
ISSN
2041-1723
Cited by
27
References
20
Language
en
Licence
Funders
U.S. Department of Health & Human Services | National Institutes of Health (R01CA130908, R01CA271486)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis. https://app.cochat.ai/papers/10.1038/s41467-023-40352-4
The paper
Ding, D., Blee, A. M., Zhang, J., Pan, Y., Becker, N. A., Maher, L. J., Jimenez, R., Wang, L., & Huang, H. (2023). Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis. Nature Communications. https://doi.org/10.1038/s41467-023-40352-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.